This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:therapeutic_probe [08.06.2017] – [Notes and comments] sallieq | home:starting:therapeutic_probe [08.06.2017] – [Therapeutic probe] removed mention of Mino from 2nd response re activation of innate immunity sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
In the context of the therapeutic probe, there are at least three responses or types of responses which indicate that continued treatment with the MP is warranted: | In the context of the therapeutic probe, there are at least three responses or types of responses which indicate that continued treatment with the MP is warranted: | ||
* **photosensitivity** – Even if patients have never been light sensitive before, they may find lights to be too bright for comfort. | * **photosensitivity** – Even if patients have never been light sensitive before, they may find lights to be too bright for comfort. | ||
- | * **noticeable spike in symptoms** – An activator | + | * **noticeable spike in symptoms** – Replacing ' |
* **noticeable relief in symptoms** – As an ARB, Benicar has profound anti-inflammatory effects, which manifest in a reduction in pain, fatigue, and other symptoms of Th1 disease. | * **noticeable relief in symptoms** – As an ARB, Benicar has profound anti-inflammatory effects, which manifest in a reduction in pain, fatigue, and other symptoms of Th1 disease. | ||
- | Symptoms which wax and wane in tandem with the every-other-day administration of antibiotics are an especially strong indication of Th1 disease. | + | Symptoms which wax and wane in tandem with an every-other-day administration of antibiotics are an especially strong indication of Th1 disease. |
It is expected that the way a patient responds to the MP will change over time. | It is expected that the way a patient responds to the MP will change over time. | ||
Line 82: | Line 82: | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | --- //Sallie Q 08.06.2017// | + | --- //Sallie Q 08.06.2017// |
+ | with | ||
+ | " Replacing ' | ||
* Legacy content | * Legacy content | ||
* http:// | * http:// |